List of Vaccines Companies in United States - 330

At 100XBIO we strive to deliver 100x more data on antigen specificity of the T cells in the limited sample volume (blood, tumor, lymph nodes), and as the downstream -- confirming the cells' phenotype and cytokine expression. Looking for (1) early investments, (2) R&D partners, and (3) early academia, biotech and pharma clients. We are raising $500K of pre-seed investment, and raised over $200K.

3T is an immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations. By leveraging the power of the immune system to recognize, target, and destroy cancer cells, 3T's technology is advancing the development of next-generation therapies that have the potential to be safer, more effective, and even curative for difficult-to-treat cancers.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world's most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients' team – helping them advance today's ideas into tomorrow's medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL acquired all the patents and IP rights from TherapyEdge, Inc. in 2005 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. COVID-19: CE mark (07/2020)

Like it's predecessor, the Infectious Disease Reseach Institute (IDRI), the Access to Advanced Health Institute (AAHI) focuses on creating technologies that improve the body's response to disease.AAHI is a nonprofit biotech organization that works on a comprehensive approach to developing new solutions for infectious disease.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

Addison Biological Laboratory, Inc. is a Fayette, MO based manufacturer and marketer of exclusive veterinary technologies. For over a third of a century, J. Bruce Addison, president and founder, has been recognized as a leader in veterinary diagnostics and herd specific bacterin production. The reputable MAXI/GUARD® product line is best known for its M. bovis (pinkeye) cattle bacterin among bovine veterinarians and Nasal Vac (intranasal respiratory) baby pig vaccine among swine practitioners. Both technologies are recognized as efficacy leaders and privately labeled for large multinational biological manufacturer/marketers. Companion animal product offerings in veterinary dental home care, dermatology, otology, and wound care provide medical researched technologies that define today’s zinc-based product standards. Marketing accomplishments include a successful export history to over 25 countries and recognition as Missouri’s Exporter of the Year. The U.S. Chamber of Commerce selected Addison Biological Laboratory, Inc. as the recipient for its prestigious Regional Blue Chip Enterprise Initiative Award. “Our mission is to be the premier provider of exclusive and innovative technologies to assist the global betterment of animal care by solving problems for veterinary professionals, animal producers, and pet owners.”

Aditxt is a social innovation platform. Every year, billions of individuals face health challenges such as autoimmune diseases, misdiagnosis, infectious diseases, organ failure, reproductive health issues, malnutrition, cancer, as well as barriers to accessing healthcare. Innovations with immense potential to address critical healthcare challenges are all around us. Untapped innovations hold the key to transformative solutions. Socially owned and capitalized as  a Nasdaq listed company with a mission of discovering, developing and deploying promising health innovations. Now is the time to inspire and mobilize the social capital inherent in a global community of stakeholders to actively participate in the discovery, development, and implementation of health solutions that could benefit humanity.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world’s most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients’ team – helping them advance today’s ideas into tomorrow’s medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat existing, emerging, and future contagions. Our nucleic acid delivery technology Fusogenix PLV stems from more than a decade of research and development in gene delivery. We actively leverage the Fusogenix PLV platform to accelerate the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFS TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

agilvax.com is your first and best source for all of the information you’re looking for. From general topics to more of what you would expect to find here, agilvax.com has it all. We hope you find what you are searching for!

AIVITA Biomedical is an Irvine, CA based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development. These proprietary capabilities enable us to turn therapeutic discovery into reality, developing revolutionary cell-based treatments and healthcare products for the patients who need them. AIVITA is developing treatments for cancer, vision loss, and is bringing next-generation skincare formulations to consumers through its commercial product offerings.

Alfa Wassermann Diagnostic Technologies is a provider of medical diagnostic instrumentation and reagents to the physician office, veterinary lab, and biopharmaceutical markets.

Aloe Therapeutics is a biotech start-up aimed at delivering cancer cures. We have designed a therapy, termed Allo-Immunotherapy (AIM), to trigger an influx of activated immune cells to traffic to the tumor microenvironment - turning "cold" tumors "hot" and "hot" tumors "hotter." INFLAME WITH AIM.

Alopexx Enterprises works with scientists and entrepreneurs to build successful new companies. We invest in novel health care technologies at all stages of development and can serve as a lead investor or collaborate with a group of investors to advance important science. We also have the capabilities to provide management and development expertise where needed. To date, our initial investments have ranged from $1-20M. The Alopexx team consists of experts who have deep industry knowledge and technical expertise in all areas of drug development including, pharmacology, CMC, toxicology, medical and clinical operations, quality and regulatory affairs. We form collaborations with academic institutions, biotech and pharmaceutical companies to advance our portfolio companies to deliver breakthrough therapies to patients in need. Our business model is to invest and develop to an important inflection point and then partner the asset for further development and/or commercialization. Portfolio companies include: -Alopexx Pharmaceuticals -Alopexx Oncology -Alopexx Vaccine -Valerion Therapeutics -Janus Biotherapeutics -Cognoptix

Alpha-1 Biologics is a biotherapeutics company developing innovative treatments for cancers and immune deficiencies. The company is dedicated to their mission to develop patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of α1PI, and in the most prevalent cause of immune deficiency, malnutrition. Alpha-1 Biologics is currently testing their orally-available, small molecules in studies to determine their ability to increase the number of tumor infiltrating CD4+ T cells and coordinate with immune checkpoint inhibitors to eliminate tumors. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). P

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company’s lead product candidate is AL001 for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient’s immunological system to Alzheimer’s. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

CenExel ACT is dedicated to performing medical clinical trials to find new patient therapies in unique areas, including Japanese-and Chinese-bridging studies. Our Phase I Clinical Pharmacology Unit is a 30,000 SF, state-of-the-art, 90 beds, clinical research center, and features: Private patient rooms and ward setting, State of the art entertainment 24-hour medical coverage, 7 days a week, On-site Surgery Suite (2 Procedure Rooms, 3 Recovery Beds), Emergency Room and Intensive Care Unit located close by In the clinical trials area, we ffer investigational therapies for indications such as Migraines, Insomnia, Chronic Pain, Osteoporosis, Hormone Replacement Therapy, Diabetes and much more. We offer new and existing therapies that manage conditions where other medical therapies may have failed. Each and every CenExel patients receive the highest quality medical care. We notify the patient's primary care physician of enrollment and ongoing status and provide a full report at the conclusion of each study. To learn more about working with us as a Sponsor or CRO for your clinical trial visit CenExel.com/ACT or call 714-774-7777.

Anivive is focused on reshaping pet healthcare by bringing together experts in software development, veterinary medicine, and clinical research to accelerate the development of novel therapeutics. Anivive. Smarter for pet health.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Antigen Discovery, Inc. (formerly ImmPORT Therapeutics, Inc.) provides research services and products specializing in high throughput protein microarray technology that simplifies proteomic biomarker discovery and enables serological and immune profiling of whole proteomes.

Applied Bio Tech Institute is a biotechnology company that develops animal-free health and environmental products, including oral vaccines, animal-free protein products, natural sweetener, and feed enzymes.

Develops DNA Security Tags, Molecular diagnostics, and vaccines.COVID-19: Applied DNA and Takis Biotech completed the design of a diagnostic kit for SARS-COV-2 (the virus that causes the disease COVID-19) being developed for production via the company’s proprietary PCR-based DNA (LineaRx™) manufacturing process. They also work with Takis on vaccines. EUA (05/2020)

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Aquatactics provides the following services related to fish health: Fish Health Products Veterinary + Regulatory Consultation Pathology Services Fish Health Education + Stockmanship Training Vaccination Protocol Design

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries).

ArkeaBio is a company focused on developing technology to reduce greenhouse gas emissions from the agricultural industry, specifically targeting livestock methane emissions. The company was founded on the premise that a simple vaccine could be a powerful tool in fighting climate change.

Arko Labs is a veterinary pharmaceutical company that specializes in developing and manufacturing industry-leading swine and turkey vaccines for commercial use.

Based in North Brunswick, New Jersey, Ascendia Pharmaceuticals is a specialty contract development and manufacturing (CDMO) company dedicated to delivering sophisticated formulations of existing drug products, and enabling formulations for preclinical- and clinical-stage drug candidates. Ascendia Pharmaceuticals is your ideal partner for: · Early stage IND-enabling formulations for toxicology and pharmacokinetic (PK) studies · Rapid development through Phase I CTM materials for oral and parenteral dosage forms · Fast discovery formulation support · Formulation development and CTM manufacturing for specialty pharmaceuticals Ascendia Pharmaceuticals also provides special development programs: · Formulations for poorly soluble and low bioavailability drugs · First-in-man injectable formulations · Nano-emulsion and nano-particle formulations · Peptide formulations · Sustained release by parenteral or oral routes · Development of 505(b)(2) products · Development of complex generics · High potency and DEA controlled drug substances · Ocular formulation development · Animal health formulations

A devision of ATTWILL Vascular Technologies, Attwill Medical Solutions purchased the assets of Anteco Pharma facility In 2017. Attwill Medical Solutions specializes in the lyophilization and related processing of pharmaceutical intermediates, medical devices and specialty food and nutritional ingredients. ATTWILL operates a fully integrated commercialization business within a 36,500 square foot facility that includes R&D laboratories, piloting facilities and seven ISO 7 cleanrooms for manufacturing. Our ISO 13485 2016 manufacturing includes six freeze dryers that are used in the processing of ATTWILL products and in contract manufacturing of products that include pharmaceuticals, drug ingredients, medical devices, and nutraceuticals

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.

Avid Bioservices (NASDAQ:CDMO), is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology, biopharmaceutical, and cell & gene therapy industries. With over 30 years of experience, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Avid Bioservices positions are accessible via the Avid Bio Careers page at https://avidbio.com/careers/.

Specialty oncology-focused biopharmaceutical company based in Malvern, PA with a broad pipeline encompassing novel best in class selective HDAC6i immunomodulators and a game changing myeloid based discovery platform. Avstera focuses on foundational tumor biology science, while methodologically breaking barriers using cutting-edge approaches in order to deliver impactful treatments to cancer patients.

As the largest not-for-profit health system in the state of Texas, Baylor Scott & White promotes the health and well-being of every individual, family and community it serves. It is committed to making quality care more accessible, convenient and affordable through its integrated delivery network, which includes the Baylor Scott & White Health Plan, Baylor Scott & White Research Institute, the Baylor Scott & White Quality Alliance and its leading digital health platform – MyBSWHealth. Through 51 hospitals and more than 1,100 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White today serves more than three million Texans. For more information, visit: BSWHealth.com.

TheBEI ResourcesRepository is a central repository, established by the National Institute of Allergy and Infectious Disease, that supplies organisms and reagents, such asSARS-CoV-2, to the broad community of microbiology and infectious diseases researchers.

Benchmark Research, an Avacare business, has a track record of safety and expertise, having conducted more than 1,000 trials since 1997 at clinics located in California, Louisiana and Texas. Benchmark's superior team of motivated and focused investigators offers clinical trials experience in a wide range of therapeutic areas. Our knowledgeable investigators enthusiastically embrace clinical research and the opportunities that new therapies bring to the marketplace and patients. Dedication and experience aside, our investigators are also highly trained in GCP and FDA regulations.

A small, agile CRO. The primary function of the scientists at BioAnalysis, LLC is to provide a collaborative workspace that enables productive and effective solutions to the client’s problems. The traditional CRO model works well, however, at BioAnalysis, LLC we believe that collaborative interactions, communication and robust experimental design along with gold-standard quality results are the true value-added. The scientists of BioAnalysis, LLC possess a wealth of experience in characterization of therapeutic proteins, mAbs, and ADC (DARs), non-biologics (Polymers, PEO/PLA, nanoparticles), ICH/FDA regulatory applications, process development, and assessment of final biologic product formulations. Our subject matter expertise in the areas of Biophysics and Proteomics is showcased in over 70 peer reviewed publications.

BioCytics via the Human Applications Lab is focused on bringing personalized oncology treatments to the market. BioCytics has an ongoing IRB-approved clinical trial (BioCytics 0001; NCT00571389) that allows for the collection and study of blood and tissue samples from consenting cancer patients. We are incubated within Carolina BioOncology - a preferred cancer treatment and Phase I drug testing facility. BioCytics was founded by Dr. John Powderly, MD, medical board certified oncologist and a certified physician investigator (CPI), who is also president of Carolina BioOncology Institute (CBOI).

BioFactura develops and commercializes biodefense drugs, novel drugs, and high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal choice for bringing these products to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer. As a result of BMI’s elucidation of “Deceptive Imprinting,” a mechanism of antigenic variation used by microbial pathogens and cancer cells to evade the host immune system, BMI developed “Immune Refocusing Technology” to circumvent such evasion mechanisms. Through the application of IRT, BMI strives to: (1) generate vaccines against pathogens for which no effective vaccine exists and (2) improve upon current strain-limited or serotype-limited protection of commercially available human and veterinary vaccines. IRT is able to alter the natural antigenicity and immunogenicity of targeted protein antigens making it a valuable tool to induce and select monoclonal antibodies. IRT can also be utilized to immune dampen therapeutic proteins and biologics to improve biological half-life and safety profiles.

Biologics Resources, LLC (BRLLC) is a Vaccines, immunotherapeutics and Biopharmaceuticals technology company.

For over 30 years, Bionique Testing Laboratories has been a trusted partner and global leader of Mycoplasma Testing Services for the life science industry. Bionique offers the full breadth of GMP services from Lot & Final Drug Product Release Testing to Real-Time PCR assays. Our service portfolio and depth of expertise enables us to support our clients’ needs from concept through clinical trials to commercialization for biopharmaceutical and cell therapy products. Our capabilities extend to successful method development and validation inclusive of rapid microbiological methods to generate real time results. Bionique stands ready to provide the highest quality of mycoplasma testing services to ensure the integrity and biosafety of your therapeutic products. Mycoplasma Testing Solutions for: • Cell and Gene Therapy Products • Clinical Trial Materials • Biopharmaceuticals • Master and Working Cell Banks • Raw Materials • Vaccines Bionique is a cGMP compliant, FDA-registered facility.

For over 30 years, Bionique Testing Laboratories has been a trusted partner and global leader of Mycoplasma Testing Services for the life science industry. Bionique offers the full breadth of GMP services from Lot & Final Drug Product Release Testing to Real-Time PCR assays. Our service portfolio and depth of expertise enables us to support our clients' needs from concept through clinical trials to commercialization for biopharmaceutical and cell therapy products. Our capabilities extend to successful method development and validation inclusive of rapid microbiological methods to generate real time results. Bionique stands ready to provide the highest quality of mycoplasma testing services to ensure the integrity and biosafety of your therapeutic products. Mycoplasma Testing Solutions for: • Cell and Gene Therapy Products • Clinical Trial Materials • Biopharmaceuticals • Master and Working Cell Banks • Raw Materials • Vaccines Bionique is a cGMP compliant, FDA-registered facility.

BIOQUAL, Inc. is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and has a long history of providing state-of-the-art facilities and trained, experienced research scientists, veterinarians and animal care personnel for clients involved in infectious disease investigations, cancer research, and a wide variety of other in vivo and in vitro studies.

BioTechLogic, Inc. is a biopharmaceutical and technology management firm with a unique, proven capability to rapidly and successfully bring products to market through the augmentation and optimization of a corporation's technical resources. We are a team of professionals with expertise in process development, BioAnalytical services, process validation, project management, quality assurance, regulatory submissions and Pre-Approval Inspection (PAI) readiness. Our quality by design (QbD) approach enables us to effectively provide product development support, including: development reports, design of experiments, technology implementation, critical process parameter evaluation, technology transfer and scale-up, and on-site third party contract manufacturing support.

Blue Heron has been collaborating with some of the most brilliant minds in the industry to create millions of complex genes using our proprietary GeneMaker® multi-technology platform. We are the first gene synthesis company founded and solely operated in the USA. Our only location in Bothell, Washington subjects us to strict U.S. standards for Intellectual Property (IP) Policy and ensures every contract for each customer is confidential. Because of our simple flat rate pricing, we deliver what no other company can provide — the assurance your project will proceed as quoted. Utilizing high grade reagents and proprietary technology we produce DNA of the utmost quality. Our aptitude for projects involving unusually long or difficult sequences allows clients to eliminate errors, risk, and costs that are simply no longer a necessary part of the research process. Blue Heron Provides: - Dedicated Customer Service - Simple Pricing - Easy Ordering - Strict Client Confidentiality - Guaranteed Turnaround Time - Sequence Design - Synthesis of Genes up to 50KB - Complex Genes (hairpins, repeats) - 100+ IP free Expression Vectors - Free Codon Optimization - Free Archiving Publications Citing Blue Heron Biotech Gene Synthesis: http://www.blueheronbio.com/assets/documents/citations/BlueHeronBiotechCitations.pdf

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.

BIB is a full service CDMO partner offering cGMP and non-GMP mammalian, microbial, gene therapy and cell therapy services.

Privately owned biopharmaceutical company pioneering the use of anti-somatostatin vaccine use. Our products (under the trademark Somatovac) have been used for treatment of metaboloic conditions, such as obesity, and productivity enhancement (livestock). Braasch has a US and international patent portfolio for our core technology (protein), application as vaccines, adjuvants and metabolic adjustment.

Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Bryllan is a contract manufacturing company that specializes in producing potent and cytotoxic compounds meeting US FDA and global regulatory standards.

Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market opportunities with mitigated clinical risk.

Calviri’s mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine. For more information, please visit www.calviri.com.

Cambridge Technologies is an independent owner-operated custom vaccine company working with veterinarians and livestock producers to provide solutions to animal health problems. We use cutting-edge molecular diagnostic and manufacturing techniques to manage the entire custom vaccine process and to provide you with the best possible solutions for managing emerging health problems. Diagnostic and research scientists work in a modern laboratory specializing in personalized service. Techniques including metagenomics, genetic sequencing, qPCR, culture, sensitivity and serology will be employed as needed to precisely determine the right isolates needed for vaccine production. Research scientists alongside the diagnosticians keep Cambridge on the cutting-edge of isolate identification and characterization. Cambridge Technologies vaccines are formulated and produced at our USDA-licensed 37,000-square-foot manufacturing facility featuring a state-of-the-art fermentation suite. The vaccine production team has extensive experience in diagnostics, R&D, quality control, regulatory affairs, and both commercial and custom vaccine production. Vaccines from Cambridge Technologies are truly customized to the customer’s needs, including a range of adjuvant choices, label options, and SoliDose implant delivery in bovine products.

CancerVAX is a drug development company focused on developing novel therapeutics in the oncology space. In partnership with the UCLA School of Medicine, we are progressing two programs: 1) Ewing sarcoma; 2) Universal cancer vaccine. CancerVAX is privately funded

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications. Candel’s products are designed to improve survival while maintaining quality of life – from early- to late-stage disease.

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.

CastleVax uses Newcastle Disease Virus (NDV) as a platform for rapidly developing safe and highly immunogenic viral vectors for use as vaccines, that are easy to deliver and store, and can be administered via injection or intranasally.

We are the only Catholic college founded by U.S. bishops. Part of a consortium of universities in Washington, DC, CUA offers more than 250 academic programs.

Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious diseases, rare diseases and cancers.

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody-drug conjugates, immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications.

Centivax’s mission is to accelerate the world’s transition to a post-pathogen humanity.

At Cerba Research we provide world-class clinical research to help life science companies successfully develop the predictive and precision medicines of the future and help people live healthier lives. We are committed to delivering the next generation of healthcare by transforming research and advancing health together. We support you with industry-leading excellence in oncology, virology, vaccine development, immunology, and cell and gene therapy, together with world-class deep specialty testing, from next generation sequencing to flow cytometry, molecular diagnostics, IHC & and spatial Omics, and bioinformatics. We are committed to helping you deliver the next generation of human-centric healthcare, by transforming research, and advancing health together. Uniquely, we combine the experience of specialty laboratories with the global reach of a central lab. We have a worldwide network of 1000 labs, hold data from over 85 million patients across five continents, and have the ability to sequence 1000-plus whole human genomes per week. This unparalleled approach to patient data gives you the opportunity to have one partner for all your test services, with consistent access and support across all clinical trial phases.

Dozens of animal vaccines

CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

Chondrex, Inc. has been shaping the landscape of arthritis and inflammation research worldwide since 1996. Chondrex was initially focused on providing scientists with the tools necessary to study the pathogenesis of Rheumatoid Arthritis (RA) as well as to develop and screen potential therapeutics for RA. Over the past 20 years however, our scope has expanded beyond just RA research. We now offer a plethora of products ranging from collagen and monoclonal antibody reagents to a wide variety of assay kits for use in allergy, arthritis, connective tissue, and nephritis related research. One such product line, the Collagen Antibody-Induced Arthritis (CAIA) cocktails, allows for faster and more consistent dosage dependent induction of arthritis in mice than the Collagen Induced Arthritis (CIA) model. Furthermore, the CAIA model can be induced in almost all strains of mice, (including CIA-resistant, T-cell deficient, gene knockout, and transgenic mice) whereas the CIA model requires a restricted haplotype. Chondrex is committed to providing the highest quality and most reliable products in order to accelerate the rate of discovery in arthritis and inflammation research.

Citranvi Biosciences is a pre-clinical stage company engaged in the design and development of novel systems and tools for immunogenicity enhancement applicable to Vaccines Research and Development. We are developing innovative and proprietary vaccine technology platforms and products, using comprehensive structure-based vaccine design, broadly applicable to a variety of preventable disease targets, where there is an unmet global medical need.

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

Clarus Biologics was launched to increase the availability of safe and effective prophylactic and therapeutic technologies. It’s lead product is a next-generation vaccine Virus Like Particle intended to enhance the effectiveness, efficiency and availability of vaccines.Clarus Biologics is Dedicated to the Discovery and Development of Novel Vaccine and Immunology Technologies

ClearB is working to develop therapeutic vaccines designed to redirect patients’ immune systems toward functional cure of hepatitis B.

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.

Colorado Serum Company specializesin manufacturingUSDA-licensed large animal biologicals, Colorado Serum Company’s product line includes Serum Antibodies, Bacterins, Toxoids, Bacterin-Toxoids, Antitoxins, Spore, and Modified Live vaccines.

CONTRACT PHARMA is the multi media information outlet dedicated to bio/pharma outsourcing. From drug development to manufacturing, we cover the latest developments, views and opinions from industry leaders in print and online. CONTRACT PHARMA offers advertising opportunities in our print magazine, Contract Pharma Direct weekly e newsletter and on contractpharma.com. We are the only worldwide print publication focused on Bio/Pharma contract services, delivering a total qualified circulation of 20,013. (VAC audit statement) On Sept. 26-27, 2024 CONTRACT PHARMA will host its 23rd Annual Contracting & Outsourcing Conference & Tabletop Exhibition. This event brings together speakers from the FDA, industry leaders, and expert analysts to discuss issues critical to success for Pharma & Biopharma outsourcing. The one-day Tabletop Exhibition of 160 top contract service providers provides great exposure to outsourcing decision makers. CONTRACT PHARMA's Corporate Capabilities and Contract Services Directory is the largest single source for company profiles and contract services. This standalone print issue showcases the services of Bio/Pharma contract service providers. The Contract Services Directory is also available online at www.contractpharma.com/csd. It's an indispensable guide for contract services in print and online. Every week, thousands of Bio/Pharma outsourcing professionals go to www.contractpharma.com to read current features, find archive stories, and get breaking news and online exclusives. We also e-mail CONTRACT PHARMA DIRECT, our weekly e-newsletter, to more than 20,000 people. CPDirect is filled with the latest news, our most recent articles, and links to our popular annual features and upcoming meetings. Free subscriptions are available on our website. Contact us for more information on how your company can get involved with Contract Pharma.

Corner is pioneering a new class of immunotherapies. Our versatile dendritic cell hyperactivation (hDC) platform is unique in its ability to address a virtually unbounded range of cancers and infectious diseases. Our platform technology induces exceptional memory T cell responses that provide robust and durable immunity. Corner seeks to transform standard of care, ushering in a new era of robust, rapid, patient-friendly and low-cost immunotherapies – even for the most difficult to treat diseases.

Creative Biostructure is specialized in providing cost-effective contract services to both academia and biotech/pharmaceutical industries in the field of structural biology and membrane protein technologies. We have developed all-in-one, gene-to-structure pipelines for the structure determination of macromolecules of your interest. With a team of experienced professionals, Creative Biostructure is able to solve the structure of many challenging proteins including GPCRs, ion channels, transporters, enzymes and viral targets. We also provide a comprehensive list of products and other related services to facilitate your research in structural biology. Creative Biostructure has also built up a unique and comprehensive Membrane Protein Screening Platform. Aiming at elucidating the fundamentals of membrane protein systems, we provide gene-to-structure services on the purification, crystallization, structure determination and analysis of various membrane proteins. With our state-of-the-art platforms, we are offering our customers access to the latest tools, techniques and expertise for their structural biology projects with competitive pricing and short turnaround time. Our staff will be very glad to discuss the details of your project and develop experimental strategies tailored to your requirements.

Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Cuervo's goal is to rapidly advance innovative new vaccine candidates from the research laboratory to the clinic by joining forces with the South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

It all started 40 years ago, when we dedicated ourselves to finding scientific solutions using components from natural sources such as Quillaja and Yucca. Since then, Desert King has been leading the way in responsibly sourcing and reliably delivering saponin based products to the world. We are a company based in the United States, Chile, and Mexico. From these locations, we supply products to more than 1,000 customers worldwide, all of whom endorse the quality of our products. We maintain long-term relationships of trust with our customers, reaching more than 60 countries. Our high value-added products provide solutions to global needs in a variety of industries, such as health, human and animal nutrition, cosmetics, mining and agriculture. This includes our QS-21, which is globally accepted as the human vaccine adjuvant quality benchmark. As pioneers in Quillaja domestication with more than 15 years of experience, we have established plantations to meet the growing worldwide demand while safeguarding the integrity of the native forest. Additionally, Desert King actively contributes to the protection and recovery of Quillaja Saponaria forests through sustainable development and harvesting techniques.

Diakonos is a clinical-stage biotechnology company developing a groundbreaking Dendritic Cell Vaccine (DCV) for difficult-to-treat cancers.

DNARx is a company developing multiple therapeutics for major unmet medical needs, with demonstrated vaccine capabilities as well as protein expression. The company has been awarded a DARPA contract for up to $10.7 million to develop medical countermeasures against biological threats.

The Duke University Clinical Laboratoriesemploy a wide range of practices; from high-throughput, highly automated testing in their hematology, chemistry and immunoassay laboratories, to specialized mass spectrometry and molecular based testing in many of their subspecialty labs, to direct patient care bytransfusion services physicians. In total last year, their 850 clinical laboratorians deliveredover 10million resultsto support the care of the many hundreds of thousands of patients who came to Duke.In additional to supporting the clinical mission of DUHS, theyalso support the other two missions of theiracademic health care system: teaching and research.

Dyadic International, Inc. (Nasdaq: DYAI) - We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines.

GDIT is a global technology and professional services company that delivers consulting, technology and mission services to every major agency across the U.S. government, defense and intelligence community. Our 30,000 experts extract the power of technology to create immediate value and deliver solutions at the edge of innovation. We operate across 30 countries worldwide, offering leading capabilities in digital modernization, AI/ML, Cloud, Cyber and application development. GDIT is part of General Dynamics, a global aerospace and defense company. We have shared our clients’ sense of purpose for over half a century and have a have a unique understanding of their missions, complex environments, and a rapidly changing world. Together with our clients, we strive to create a safer, smarter world by harnessing the power of deep expertise and advanced technology.

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs - Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.

At Elanco, we work to improve the health of animals through innovative products and services for pets and farm animals around the world. As a global animal health company, we provide solutions that empower our customers to advance a vision of Food and Companionship Enriching Life. Since 1954, Elanco has committed to empowering veterinarians, farmers, and all those who care for animals with the tools they need to help animals live healthy lives. Healthier animals are the key to making our lives better - This is the fundamental belief uniting all global Elanco employees. That's why we are committed to the idea that our business can be a unique force for good for all in society. Through our Elanco Healthy Purpose™ framework of Environmental, Social and Governance (ESG) commitments, we focus on delivering sustainable solutions to advance the well-being of animals, people and the planet. This program also enables our employees around the world to take paid time off to make an impact as a volunteer, offering their time or talent to give back to our customers, causes and communities. #ElancoHealthyPurpose #WeAreElanco

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity's greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio's lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio’s Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead product is the TLPO vaccine, an autologous therapeutic cancer vaccine designed to stimulate the immune system to recognize tumor cells and fight a patient’s specific cancer. Therapeutic cancer vaccines are an attractive immunotherapy because of their potential safety, specificity, and long-lasting response due to stimulation of immune memory.

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 11th largest company in Indian Pharmaceutical Market as per AWACS MAT Feb'24 data.

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Emmune, Inc. is a start-up biotechnology company that has a novel approach for treating and preventing HIV infection. We engineered a synthetic antibody from the receptors that HIV uses to infect T cells, CD4 and CCR5. Because this synthetic antibody, known as “eCD4-Ig,” is built from the viral receptor and co-receptor, it recognizes 100% of HIV-1 isolates. A single intramuscular inoculation with an AAV vector expressing eCD4-Ig protected monkeys from multiple intravenous challenges with live virus.

EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal flu vaccine that confers long-term immunity to all Type A influenza strains—including those which cause seasonal flu and influenza pandemics. Seasonal flu causes 250,000 to 500,000 deaths every year. The CDC and other experts have cautioned that we are extremely vulnerable to the catastrophic occurrence of a global flu pandemic—on a scale that could far exceed both COVID-19 and the Spanish flu of 1918. In its Global Influenza Strategy (2019–2030) report, the World Health Organization has declared the development of a universal flu vaccine as an urgent need—but the unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To address these issues, EnGen Bio is developing universal vaccines for Type A flu prevention. Effective for vaccination in both the $6B human and $0.5B veterinary markets, our antibodies also demonstrate potential for therapeutic treatment of influenza, with an additional $2B prospective market. If successful, our efforts will eradicate flu pandemics and dramatically decrease the global burden of illness and disease caused by influenza.

Engimata has a platform adjuvant technology that improves vaccine efficiency, reduces antigen dose and enhances vaccine stability outside the cold supply chain. Engimata is currently developing a vaccine against COVID-19 using its platform technology. Engimata’s vaccine is cost-effective, easy to scale up, and simple to manufacture and distribute outside the cold supply chain. This increases vaccine accessibility and stability, ultimately saving cost, resources, and lives. Vaccine wastage in the supply chain due to temperature fluctuations is a major problem for current vaccines and costs the government and WHO billions of dollars every year. In order to combat COVID-19, it is crucial to overcome transportation barriers and distribute a vaccine across the world.

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.

EpiVax uses immune-engineering to develop new vaccines and to improve the immunogenicity profiles of new drugs. The company is well known for its independent thinking and interdisciplinary scientists. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity"​ meetings. By 2006, EpiVax had developed a reputation as “thought leaders” in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to <20 for its competitors). The EpiVax team also prides itself on delivering on promises. “We maintain a close relationship with our clients,” De Groot says. We aim to treat our clients with respect and provide capable, intelligent solutions for their needs.” The company's motto is "Fearless Science"​. For up to date news about the endeavors of our Fearless Scientists, read our blog: http://epivax.com/press/thinking-out-loud-blog

Fighting the world’s most devastating diseases through the innovative power of targeted oral mRNA vaccines.

EVOQ Therapeutics is developing immunotherapies to improve the lives of individuals fighting autoimmune diseases. There are more than 100 chronic autoimmune diseases - many severely debilitating, and some life-threatening. According to the National Institutes of Health, up to 23.5 million Americans (over 7% of the population) suffer from autoimmune disease, and the prevalence is rising. Autoimmune disease occurs when the body’s central immune tolerance system fails - resulting in T and B cell-mediated destruction of self-tissues. This immune system failure is responsible for many devastating diseases including – Type 1 Diabetes, Celiac disease, Multiple sclerosis and Rheumatoid Arthritis. EVOQ’s technology unleashes and restores the body’s natural immune tolerance pathways.

EV Therapeutics is developing novel therapies to induce an anti-tumor immune response in advanced stage metastatic colorectal cancers. Our technology is based on our proprietary modified extracellular vesicles (mEVs) that significantly enhance tumor antigen-specific T cell infiltration into the tumor microenvironment and synergizes with current immune checkpoint blockade therapies. Mechanistically, our therapeutic platform activates tumor-specific T cell costimulation. Our extensive pre-clinical data show that treatment with mEVs significantly improves survival in late-stage disease models. Our findings potentially translate to a significant survival advantage for human colorectal cancer patients with advanced disease. Our modified extracellular vesicles-based therapy also controls the minimal residual disease that can prevent cancer recurrence functioning as a cancer vaccine. We are seeking out-licensing, co-development, and partnering opportunities.

ExcepGen is a venture-backed, early stage biotechnology company located in San Francisco. The company is focused on solving fundamental underlying problems in drug discovery and applying those solutions to create a new generation of therapeutics.

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. The company offers bioconjugation, protein expression, purification, immunoassay design, analytics, training, and consulting services.

Flow Pharma uses Artificial Intelligence (AI) to select small peptides called neoantigens on the surface of cancer cells optimal for killer T-cell attack identified by gene sequencing a patient's cancer cells. These peptides can be synthesized, loaded into FlowPharma's FlowVax therapeutic cancer vaccine platform, and injected into the patient to expand killer T-cells which can recognize and kill cancer cells expressing those neoantigen peptides. Flow Pharma is creating patient-specific, neoantigen based, immuno oncology therapeutics initially focused on cervical cancer (orphan drug application for advanced, metastatic disease), breast cancer and malignant melanoma.

FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in respiratory diseases.

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl.

GeneCure Biotechnologies is a biotechnology company that focuses on developing gene therapy based technologies to treat genetic and acquired human diseases.

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here. For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux. Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.

At Geneos, our passion is to develop personalized therapies to unleash the most powerful force against cancer – your body’s own immune system. Our GT-EPIC Platform is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies.

Enabling users to establish #ownership & #control over their Biosamples & derived datasets as Non-fungible Tokens. We call them #BioNFTs 🧬.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript's premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

The Georgia Genomics and Bioinformatics Core (GGBC) is the University of Georgia (UGA) core laboratory for nucleic acid sequencing and bioinformatics. Theirmission includes research support, education, and training. Theirservices are available to university and industry researchers.Theirservices encompass the range of genomic techniques and applications, sequencing technologies, and bioinformatics analyses. GGBC operates multiple platforms for short-, long-, and single-molecule sequencing reads (i.e., Illumina MiSeq and NextSeq, PacBio Sequel, and Oxford Nanopore MinIon). Theyalso write letters of support (LOS) to offer theircapabilities and expertise for grant applications submitted to funding agencies.

GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor types including breast, ovarian, gastric, liver, pancreas, renal and lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers.

Improved baculovirus / insect cell expression platform tools

GMJ Technologies, Inc. develops novel analytical technologies for efficient analytical workflows in biotherapeutic development and omics technologies

Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex's team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Halloran Consulting Group is a life science consulting firm providing strategic development, regulatory, quality, clinical, and organizational support to industry leaders in the pharmaceutical, biotechnology, and medical device sectors. Our consultants are subject matter experts with technical and strategic expertise, who deliver a tailored approach to each engagement, successfully propelling our clients to their next inflection point.

Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases.

HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases with next-generation approaches designed to enable the body’s immune system to prevent and cure disease. We have engineered our technologies to Access, Activate, and Amplify the immune system’s natural ability to create antibodies and T-cells that fight cancer and infectious diseases such as SARS-CoV-2. We are developing multiple product candidates from our proprietary discovery platforms, including LION™, which has the potential to provide health benefits to a broad patient population. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. HDT Bio offers a comprehensive compensation plan which includes health insurance for employees and dependents (inclusive of multiple plants to choose from, including a $0 premium plan with HSA and company contribution), generous PTO (11 observed holidays and week long year-end closure), stock options with Carta Tax Advisory for equity and tax support, flexible spending accounts (FSAs), commuting benefits (ORCA or paid parking), and retirement benefits with company match. HDT Bio Corp. is an equal opportunity employer committed to a diverse and inclusive workforce. This environment is encouraged by HDT's culture, which supports women in science through our Women+ group, creates inclusive events to highlight the diverse cultures represented by our staff, and with the adoption of an open office environment for all.

HelixNano is building the world's most advanced mRNA platform to enable previously impossible applications across human and non-human biology

Helmer Scientific is a manufacturer of medical and laboratory equipment with a focus on healthcare solutions.

Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”)

Feline and equine vaccines

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.

HTD Biosystems is a contract research & development organization providing development of injectable products. Founded in 2001, our services focus on the rapid advancement of proteins, antibodies, peptides and biological drug candidates from the bench to the clinic. Our capabilities include: • Formulation & Lyophilization Development • GLP Manufacturing of Tox lots • Biophysical Characterization Our experience includes solutions for developing stable injectables for biologics, high concentration proteins, poorly soluble compounds and controlled release formulations, HTD Biosystem's drug delivery technologies include: • Liposomes • Vaccines • Nanoparticles • Nano Suspensions •Lyophilized Products HTD Biosystem's analytical technologies include: • Characterization of sub-visible particles and aggregates • Solid-state characterization • Protein conformation and stability HTD has over 160 clients globally, ranging from small to large pharmaceutical companies in the North & South America, Europe, Australia & Asia. HTD has successfully completed several pharma quality audits.

Iaso Therapeutics, Inc. is a start-up company spun out from Michigan State University. The company was founded in 2018 by Dr. Xuefei Huang. Dr. Huang is a MSU Foundation Professor jointly appointed in the Department of Chemistry and the Department of Biomedical Engineering, Michigan State University. In addition, he is a member of the newly formed Institute for Quantitative Health Science & Engineering. With over 25 years of experience, his research program is focused on the development of novel technologies for next generation vaccines, including vaccines targeting both cancer and infectious diseases. Iaso Therapeutics, Inc. aims to translate the cutting-edge technologies developed in the Huang laboratory to promote human health and treat diseases.

Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.

Imanis Life Sciences has an unwavering commitment to the advancement of science. For many companies, profitability rules decision making. But at Imanis, leading scientific breakthroughs is the primary focus. We are about making a difference in the world by putting people in a better position than they were yesterday. We strive to do this by being a leader in laboratory assays and research services to accelerate the development of a broad range of next-generation therapies.

Virology research products

ImmunityBio (previously NantKwest (NASDAQ: NK)) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells. ImmunityBio is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our “off-the-shelf” activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease. Our targeted therapeutic areas include: (1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells, (2) infectious diseases, including viral, fungal and bacterial infections, and (3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome. 1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

ImmunSYS is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other metastatic solid tumor cancers. ImmunSYS is at the forefront of an entirely new approach to treating cancer. Our platform therapy has been shown to be effective in some metastatic cancers and may have wide applications as a cancer treatment for several solid tumor cancers, with the potential for cure in some patients. The company’s revolutionary therapy, YourVaccx™ utilizes a novel combination of controlled cell lysis and a triple-component immunotherapeutic drug. This new immunotherapy focused therapy is designed to empower the immune system to recognize and selectively attack cancer cells throughout the body. The company is initially developing the new cancer therapy for the treatment of metastatic prostate cancer, with a pipeline of additional development programs for other solid tumor cancers. Our proprietary therapy was conceived by the focal prostate cancer therapy pioneer and inventor of the male lumpectomy, Gary Onik, M.D. He is not only the inventor, but also a patient. Dr. Onik developed aggressive metastatic prostate cancer in 2018 and received his own therapy. He had a complete response and remains disease-free to date. ImmunSYS is committed to bringing life-changing treatments to cancer patients by bringing the tumor to the immune system to fight cancer in a new way. We believe our new YourVaccx™ therapy has the potential to offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

Impact Biomedical, Inc. is an emerging human healthcare company and is a wholly owned subsidiary of DSS, Inc.

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.

Infinity Bio is a technology company that provides detailed insights into the immune system using its proprietary antibody profiling platform. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity's assay, MIPSA, was developed at Johns Hopkins University in Ben Larman's Lab of Precision Immunology. It builds off decades of work in the fields of genomics, proteomics, immunology, and bioinformatics. Our assay was engineered to enable best-in-class turnaround times and cost. With a team of experienced professionals and a state-of-the-art facility, we are poised to make a significant impact to research and for our customers.

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

Innovac Therapeutics is a biotechnology company dedicated to developing innovative vaccines for patients with unmet medical needs, using our proprietary RNA technology.

INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases.

The Institute of Bioinformatics's mission is to facilitate cutting-edge interdisciplinary research in bioinformatics/computational biology and its application. We train graduate students to tackle complex biological problems which utilize omics or other complex data types.

Integral Molecular is a research-driven biotechnology company specializing in antibodies, viruses, and membrane proteins. We develop technologies for solving big scientific challenges and advancing therapies against difficult-to-treat diseases. Our products, platforms, and services enable antibody discovery, biotherapeutic safety profiling, vaccine development, protein engineering, and more. Learn why top pharmaceutical and biotechnology companies trust Integral Molecular. Instagram: IntegralMolecular

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases.

International Stem Cell Corporation (OTCBB:ISCO) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. Parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpSC) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover large parts of the world’s population. ISCO plans to create a bank of these valuable hpSC lines (UniStemCell™) to serve all populations across the world. Human parthenogenetic stem cells have great therapeutic potential, yet do not require viable human embryos, thus avoiding ethical issues. ISCO’s scientists are focused on using hpSC to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells. ISCO advances and operates three businesses: Lifeline Cell Technology, Lifeline Skin Care and Universal Stem Cell Bank.

Privately held biotechnology company developing therapies for substance use disorders.

By developing novel and affordable vaccines for all populations worldwide we're addressing health inequalities and empowering people to live healthy lives Inventprise is a mission driven vaccine manufacturing company developing vaccines that have shown a more robust and broader spectrum of protection than currently marketed conjugated vaccines. Our lead vaccine candidate is a 25-valent pneumococcal conjugate vaccine (PCV) funded by the Bill and Melinda Gates Foundation (>$100M) and aimed at large-scale supply to Low-Middle Income Countries. Additionally, we have a robust pipeline of vaccines and vaccine technologies, that have both viral and bacterial applications. Inventprise was founded in 2012, and is led by founder and Executive Chairman, Subhash Kapre PhD, former SVP and Corporate Officer of Serum Institute of India and Chief Executive Officer, Yves Leurquin, former general manager of Takeda Vaccines, Europe. Inventprise is based in Redmond, Washington, we have over 100,000 square feet of recently built, state-of-the-art facilities that have the capacity for large scale volume (>150M annual doses). With over 100 employees mostly exceptionally qualified industry scientists, and manufacturing professionals, Inventprise has created a large and dynamic presence in the Washington State Life Sciences environment.

At InvivoGen, we strive to provide life scientists worldwide with innovative, high quality and reliable reagents. As specialists in cell culture engineering and innate immunity, we are passionate about designing, developing, and bringing to market new tools and services for cutting-edge research. At our three regional headquarters — in Toulouse (France), San Diego (USA) and Hong Kong (China) — and through our dedicated multilingual customer support staff, we can provide researchers around the globe with the reagents and product information that they need to make the scientific breakthroughs of tomorrow. InvivoGen is a privately held company founded by university researchers in 1977 in Toulouse, France. Since then, we have gradually expanded with the opening of InvivoGen San Diego, in 1997, and InvivoGen Hong Kong, in 2014. Our unparalleled skills in microbial fermentation enable us to produce a wide range of bioactive molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest available collection of pattern recognition receptor agonists, from various micro-organisms. Over 25% of InvivoGen’s employees hold a PhD in biology or chemistry. Through specialized R&D teams, they work together seamlessly to design, produce and validate novel plasmids, cell lines, vaccine adjuvants and synthetic ligands for research in areas as diverse as gene therapy, molecular immunology and vaccination. Moreover, based on our first-hand knowledge of innate immune receptor signaling pathways, we have devised an ever-expanding collection of reporter cell lines, including cytokine reporter cells and knockout (KO) cell lines for high-priority innate immune targets. Scientists depend on InvivoGen for quality, consistency and reliability. Whatever research challenges you are facing, count on InvivoGen to provide you with the tools and solutions that you need.

Formerly ADGI -Adagio Therapeutics, Inc., Invivyd is a biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases.​ The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. ​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape.​ The company is generating a robust pipeline of products for use in both prevention and treatment of disease. Invivyd’s most advanced pipeline candidate is adintrevimab, an investigational monoclonal antibody which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.

InvVax was incorporated in January 2013. Located in sunny Southern California, it maintains a strong affiliation with the UCLA, where its technology was originally developed. InvVax has access to a wide network of leading investigators in diverse disciplines, including molecular virology, immunology, pharmacology, and clinical infectious diseases.

Our mission is to develop a superior vaccine platform to improve clinical outcomes for cancer patients.

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company's consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.

JCVI researchers work on mammalian genomics, universal flu vaccines, autoimmune diseases, infectious disease, influenza, yellow fever, malaria, microbiology, and synthetic biology.

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to our customers across geographies. We organize our business into two segments, namely, Specialty Pharmaceuticals, comprising Radiopharmaceuticals (including Radiopharmacies), Contract Manufacturing of Sterile Injectables and Non-sterile Products and Allergy Therapy Products, and Generics & APIs, comprising Solid Dosage Formulations and Active Pharmaceutical Ingredients.

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus' natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir's cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh's world-class oncolytic virus and immunotherapy research programs.

KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 500+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. KBI is proud to be a JSR Life Sciences Company.

Solutions for the Blue Revolution Since 1996, Kennebec River Biosciences has provided comprehensive testing and health services to farms, businesses, government agencies, and scientific research institutions involved with aquatic species. Starting out small and with a focus on finfish diagnostics, KRB has expanded to new species, new products and services, and a worldwide customer base. Today, it is the largest commercial lab of its kind in the Americas. Recognized by numerous international, state, and provincial regulatory authorities, KRB performs both diagnostic and regulatory testing on all finfish, shellfish, and crustacean species. Our health solutions include KRB CustomTM vaccines, veterinary consultation, and contract research to solve aquatic animal health problems or to add value to your harvest. At KRB our job is to make your job easier. Your time and investment deserves the fastest turnaround, the most reliable results, and the most complete customer service. We are proud of our work, passionate about finfish and shellfish health, and confident that you'll be pleased with our solutions.

Khloris Biosciences is a private biotechnology company located in the San Francisco Bay Area. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells (iPSCs) for drug discovery, vaccine and cell therapies.

Kineta is a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives.

Kovina Therapeutics is a preclinical stage biotechnology company developing first-in-class antiviral therapeutics designed to treat cancers and pre-malignant infections caused by Human Papillomavirus (HPV)

L2 is a biotechnology company based in New Haven, Connecticut, USA with focus on new small molecule therapeutics, vaccines, and diagnostics

LabConnect improves lives by partnering with pharma/biotech companies and clinical research organizations (CROs) to accelerate the development of new medicines around the world. An independent, global, one-stop-shop focused on delivering central laboratory services that are tailor-made, timely, and flexible, LabConnect provides unparalleled program oversight and support to meet the evolving study demands from traditional to increasingly complex trials. With deep and unmatched experience, LabConnect's team of scientific experts serves as an extension of our client's clinical teams, quickly coordinating all laboratory-related needs and providing end-to-end analytical and logistical solutions. Offering a full suite of services from real-time sample tracking and data integration to groundbreaking scientific support services, LabConnect is the global partner of choice for central laboratory services. For more information, visit www.labconnect.com

Latham BioPharm Group (LBG), part of Sia Partners, is a leading life sciences consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies to solve complex business, regulatory, and product development challenges. Our experienced consultants come from large pharmaceutical companies, small biotechs, academia, and global CROs/CDMOs, and many have even held senior positions with government agencies. Since our founding in 1996, we have grown steadily and have built a robust capability set that has enabled us to help life sciences companies of various sizes drive long-term value into their organizations. In 2022, we became part of Sia Partners when they launched a division dedicated to life sciences consulting—a mutually beneficial merger that will open new doors as we look towards the future. Our core services include: • Product Development • Non-dilutive Funding • Strategic Consulting We are guided by value, both in our business model and in our industry-leading consulting. Our approach is scalable, flexible, and client-centric. We regard you as a partner and become a trusted part of your team. We adapt to your processes and align with your strategic direction and company objectives to generate meaningful analysis and quantifiable results. Both global organizations and emerging start-ups rely on us to guide their products and portfolios down a clear path to success. Sia Partners Sia Partners is a next-generation management consulting firm and pioneer of Consulting 4.0. We offer a unique blend of AI and design capabilities, augmenting traditional consulting to deliver superior value to our clients. With expertise in more than 30 sectors and services, we optimize client projects worldwide. Through our Consulting for Good approach, we strive for next-level impact by developing innovative CSR solutions for our clients, making sustainability a lever for profitable transformation.

Spindle Biotech Inc. (an Applied DNA Sciences, Inc. (NASDAQ: APDN) company) is commercializing a proprietary RNA polymerase for large-scale mRNA vaccine production. Recent advances in mRNA technology have shown the growing importance of synthetic RNA in biological systems due to its desirable transient property. Typical mRNA vaccine companies spend up to 60% of their cost of goods on raw materials such as enzymes and DNA templates. Spindle's platform provides a unique solution in producing high-quality RNA on-demand and in high yield, significantly reducing the cost of goods for mRNA production.

LineaRx, an Applied DNA Sciences, Inc. company (NASDAQ: APDN) delivers enzymatically-produced LinearDNA™ as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity and scalability to support the next generation of nucleic acid-based therapies. Manufactured by a proprietary, large-scale polymerase chain reaction (“PCRâ€?) based manufacturing platform, LinearDNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences.

List Labs specializes in the production of native toxins, recombinant proteins, bacterial fermentation, assay development, contract manufacturing, and biotherapeutics. List Labs produces C. difficile toxin A and toxin B, shiga toxins, cholera toxin, anthrax toxins (PA, LF, and EF), pertussis toxin, diphtheria toxin, CRM197, tetanus toxin, staphylococcal enterotoxin B, botulinum toxins as well as several types of lipopolysaccharides (LPS) or endotoxin for purchase by the research community.

Longhorn Vaccines and Diagnostics, LLC is a research company Headquartered out of 7272 Wisconsin Avenue Bethesda, MD 20814 United States. The R&D facility is at 19 Firstfield Rd Gaithersburg, MD 20878.

LumaCyte’s advanced real-time bioanalytics platform, Radiance®, is a label-free, single cell approach for quantitative characterization of innate cellular responses, without the need for antibody or genetic labeling. This revolutionary technology utilizes Laser Force Cytology™ (LFC) to measure subtle phenotypic changes based purely on the intrinsic biophysical and biochemical properties of cells in response to their environment and/or treatment.

MalarVx is a bio-pharmaceutical company located in theCenter for Infectious Disease Researchfacility in Seattle, Washington.MalarVxwas founded to address the myriad challenges of creating a safe, affordable, effective malaria vaccine using innovative new technologies discovered through research.They are focused on the development of in vitro culture systems for the malaria parasite which will lead to the development of an effective whole-parasite vaccine. Theycollaborate with researchers in non-profit institutions, university infectious disease programs, foundations committed to solving diseases of the third world, and for-profit pharmaceutical and medical devices companies.

Mana.bio is an AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

MassBiologicsis a non-profit FDA-licensed manufacturer of vaccines. For over 100 years, MassBiologics has worked to improve public health through applied research, development and production of biologic products, including vaccines, plasma derivatives and more recently, monoclonal antibodies. MassBiologics currently manufactures Tetanus and Diptheria Toxoids, Adsorbed (Td) vaccine and distributes them nationwide.

Applying breakthrough science to develop life-saving vaccines for people in need around the globe

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.

MediCell Technologies (MCT) believes that stem cells can bring unique and exceptional value to health care.We forms Strategic Partnerships with industry and academia entities to facilitate and accelerate preclinical development of stem cell therapies. We are working to advance the field of stem cell applications. Progenitor Biologics®, LLC and AT Scientific, LLC are wholly owned subsidiaries of MediCell Technologies DefenAge® is a brand of Progenitor Biologics.

Biopharmaceutical Company engaged in vaccine development against emerging viruses and biopharma CDMO manufacturing.

Megadalton Solutions is a technology company that specializes in charge detection mass spectrometry for the characterization of large molecules, helping clients quantify AAV fractions and troubleshoot large molecule formulations.

Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, co-founded Meissa. They are supported by a team with extensive experience in all aspects of vaccine development. Meissa is currently a resident company at the Johnson & Johnson Innovation – JLABS in South San Francisco.

Memgen is a clinical-stage biotech company developing viral immunotherapies to harness the power of the immune system to potentially cure cancer and to protect people from infectious diseases. The Company’s pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already demonstrated the ability to elicit powerful, antigen-specific immune responses. The Company’s lead cancer immunotherapy, MEM-288, was developed in collaboration with Moffitt Cancer Center. It is an oncolytic virus engineered to selectively target cancer cells and to supercharge the immune system through expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. MEM-288 generates a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. Memgen is close to completing the monotherapy part of a clinical trial in advanced/metastatic NSCLC. Memgen's vaccine adjuvant, MemVax, is designed to be used in combination with other vaccines to generate a strong, durable immune response. MemVax is a highly specific immune stimulant that can work with antigens across a range of delivery approaches. Memgen has over 100,000 doses of MemVax ready to go into clinical trials, and an active file with the US FDA. Memgen plans to soon begin clinical trials of MemVax in collaboration with other companies developing complementary vaccines.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Metaclipse Therapeutics is a preclinical stage biotech company developing novel cancer therapies that are tailored to each patient and their specific tumor. The Company’s first ‘personalized’ cancer therapy is for triple negative metastatic breast cancer. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019.

Micron Biomedical, Inc. is a clinical-stage biopharmaceutical company on a rapid path to bring to market drugs and vaccines that are formulated into a proprietary patch technology that simplifies and improves the way actives are delivered, stored, and distributed. This technology is designed to increase patient access to drugs and vaccines that would otherwise require expert injection and to improve safety and efficacy by skin targeting.

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity. Since the company’s inception, the founders have been responsible for funding the development of the IMT504 technology platform, investing over $23M to date. They continue to invest in this promising new therapy to develop therapies to impact disease with innovative treatments.

MRIGlobal is a world leader in applied science and technology research. We work with government agencies, commercial businesses, and academic institutions to provide independent research and innovative development. We are trusted partners steeped in technical excellence and a personal connection with each client. Contact us to learn how we can help you solve your program needs. We look forward to getting to know you.

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma.

Minerva specializes in quality investigations, product development, technology transfer and productivity improvements services for the cell and gene therapy, biotech and medical device industries, using advanced data, knowledge and risk management. Our team of interdisciplinary professionals supply us and our clients with cutting-edge knowledge while keeping our rates very competitive. Our team includes Quality Investigators, Engineers, Data Analysts, Information Scientists, and Biotechnology professionals. We also have a network of advisors in Quality Investigations, Life Sciences, Data Sciences, and Engineering. We tailor our services according to our client's location and budget needs: • Full-time Remote Work with On-Location Manager • Part-time Remote work with partial On-Location • Virtual Person-to-Person Advisory Services • Full-time On-Location • Other arrangements as needed Minerva uses process characterization and data structuring to help companies grow through continuous improvement and effective change management. Our data-driven and risk-based reports on product development and sustaining are fast, reliable, and compliant, and designed to facilitate your analysis and decision-making. We are best known for our agile implementation of databases and information management systems for tracking and visibility of medical device development, drug development and approval, methods development, sample testing, and operations sustaining. Let Minerva help your company achieve its development, operations and quality objectives through our services in Knowledge Management, Data Management, Risk Management, and Language Management.

At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.

ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and liquid tumors, as well as several of the world’s most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. ModeX is an OPKO Health company based in Natick, Massachusetts.

MDS is a contract research organization that provides molecular diagnostics and toxicology services to pharmaceutical and research institutions.

Najít Technologies is dedicated to the development of safe and effective vaccines against infectious diseases of global importance.

Nature's Toolbox, Inc. (NTx) is advancing the healthcare industry with their cutting-edge biomanufacturing solutions. NTx, based in Rio Rancho, New Mexico, is using innovative systems like NTxpress® and NTxscribe® to create life-saving medicines in an eco-friendly and sustainable way. Their proprietary biomanufacturing process uses hollow fiber bioreactors to support the increasing demand for mRNA-based vaccines and protein therapeutics. This easily scalable process enables NTx’s partners to increase production and streamline operations to meet changing global demands. To learn more about their game-changing approach, visit their website at https://www.ntxbio.com.

Robert “Tex” Walker is a veterinary vaccines manufacturer that adheres to USDA guidelines.

NEUVOGEN is an immunoncology company applying a systems approach to develop therapeutic whole cell cancer vaccines to transform how cancer is treated. Our mission is to serve patients with cancer by developing transformative therapies to meaningfully extend their lives. NEUVOGEN’s vision is to revolutionize cancer treatment by harnessing the full power of a patient’s immune system to eliminate cancer from their body. We have taken a fundamentally different approach to solving cancer. Unlike other early-stage immunoncology companies, we try to solve for multiple issues arising from the complexity of cancer biology. Our approach to solving cancer is based on the concept that in order to fully address the complexity of solid tumor cancer biology, many targets and multiple biologic pathways need to be addressed simultaneously. NEUVOGEN is advancing a broad pipeline of therapeutic whole cell cancer vaccine candidates designed to activate the patient’s immune system to target and eliminate existing tumors and prevent future metastases. Our research programs focus on therapeutic cancer vaccines to treat a wide range of tumor types across numerous solid tumor indications.

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q² Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies. The Company’s platform technology, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system. The dendritic cells are extracted from the body, loaded with tumor biomarkers or ‘‘antigens’’, thereby creating a personalized therapeutic vaccine. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The Company’s lead product candidate is DCVax®-Brain which targets Glioblastoma Multiforme (‘‘GBM’’), the most lethal form of brain cancer. DCVax®-Brain has entered a Phase II FDA-allowed clinical trial, which is designed and powered as a pivotal trial (i.e. a trial from which a company may go directly to product approval). Following this trial, the Company anticipates filing a biologic license application (or ‘‘BLA’’) with the FDA for DCVax®-Brain. DCVax®-Prostate, which targets hormone independent (i.e. late stage) prostate cancer, has also been cleared by the FDA to commence a Phase III clinical trial, which is also designed and powered as a pivotal trial.

Novatein Biosciences is a rapidly growing biological reagents company specializing in the production and supply of immunoassay kits, reagents and proteins to the researchers worldwide. We supply more than 10,000 different types of proteins and antibodies, and have one of the richest supplies of validated ELISA kits. In addition, we function as a contract research organization (CRO) assisting our clients in protein/ antibody production and immunoassay development and setup. As a manufacturer of reliable ELISA kits, our scientists are experts in performing and troubleshooting different types of sandwich assays including ELISAs. Our laboratory in Woburn, MA is equipped with BSL2 cabinet, CO2 incubator, shakers, incubator-shakers, ELISA plate washer, ELISA plate reader, protein spotter, array imager, FRET and alphascreen plate reader, qPCR cycler, gel documentation system, freezers, refrigerators, fume hoods, centrifuges, pH meter, western blot apparatus, PCR machine, FPLC/HPLC instrument, microscope etc. Our mission is to accelerate R&D by providing high quality reagents and timely services. At Novatein Biosciences, we firmly believe that we can only reach our potential as a company when our clientele succeed with their independent research goals. As such, we are completely committed to becoming a key partner for each of our clients’ biomedical research needs.

We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Our mission is to develop effective and affordable preventive vaccines for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. Using our universal vaccine platform for Alzheimer’s, our goal is to induce antibody titers high enough to penetrate the blood-brain barrier and prevent pathological plaques, fibrils, and oligomers to delay disease onset in cognitively unimpaired people at risk of Alzheimer’s.

Ocean Biomedical is a new-generation biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We're working to bring together the interdisciplinary expertise and resources required to develop a diverse portfolio of pharmaceutical inventions and technologies through preclinical, clinical, and commercial development. We aim to build a continuous pipeline of drug development opportunities through our relationships with universities and medical centers. Our current product candidates consist of preclinical programs each with potential for broad application in oncology, fibrosis, and the treatment and prevention of severe malaria. Our programs in oncology and fibrosis are based on discoveries of disease pathways and related drug targets emerging from pioneering work in the field of chitinase biology by our scientific co-founder, Jack A. Elias, M.D., a pulmonary specialist who was formerly the Dean of Medicine at Brown, and the Chairman of Medicine at Yale. In infectious disease, we are developing both therapeutic and vaccine candidates against malaria, a disease that kills 500,000 children and infects 200-300 million people globally each year. Our malaria program is built on the discovery by Jonathan Kurtis, M.D., of two novel malaria antigens, PfSEA-1 and PfGARP which have shown a significant reduction in malaria parasites under multiple levels of in-vitro and animal model testing. (press links below). Kurtis is the Chairman of Pathology and Laboratory Medicine at Brown and the founding director of the Center for International Health Research.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.

Omniose was founded in 2016 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has been awarded $11.2 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae. Omniose announced an expansion of the team in April 2022 with the addition of Timothy Cooke as CEO and Roman Fleck as Chairperson. Both of these highly experienced executives are based in the Boston area. The company also announced the formation of a Scientific Advisory Board with co-founder Mario Feldman and Steven Projan, who brings deep industry experience in infectious disease drug and vaccine development.

Onconetix (formerly Blue Water Biotech Inc.) (Nasdaq: BWV) is a biopharmaceutical company focused on developing transformational therapies to address significant health challenges globally. The company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children.

Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell focused technologies are designed to be used on their own or in combination with other immunotherapeutics.

Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. We promote Hiltonol® (poly-ICLC) as an experimental viral mimic and broad activator of innate and adaptive immunity. While initially developed as an interferon inducer, Hiltonol® has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Optimeos Life Sciences is pioneering a novel targeted gene delivery approach to advance medical treatment and patient care.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.

Oravax Medical is developing an oral COVID-19 vaccine. The Oravax technology seamlessly integrates a novel approach to vaccines with a proprietary oral delivery platform. Oravax's COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus. The oral delivery of the vaccine ought to allow for widescale inoculation and easier distribution of the vaccine without requiring an injection. Oravax was established by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech with a mission of bringing an oral COVID-19 vaccine to the market.

Orbital Therapeutics is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of RNA-based medicines to treat disease in humans.

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.

Orna Therapeutics is a biotechnology company reshaping RNA therapeutics. We are developing the leading circular RNA technology platform (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions – unlocking the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies for the treatment of disease. Website: www.ornatx.com

OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors.

PAI Life Sciences is a biotechnology company located in Seattle, WA, specialized in the developmental and translational research necessary to bring products from the laboratory to bedside. Its mission is to address neglected diseases throughout the world with the idea of “serving the underserved.” The company has developed novel protein biotherapeutics and has a pipeline of products ranging from infectious disease vaccines and adjuvants to therapeutics for cancer.

PATH is a global team of innovators working to accelerate health equity so all people and communities can thrive.

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.

PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company. We develop novel combination and immunotherapies to treat cancer by bringing complementary biological pathways together to achieve synergistic clinical benefit. Our therapeutic candidates bridge the innate and adaptive immune systems by generating profound CD8+ T cell production. Our pipelines are patented AIRISE (Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors) and ARAC (Antigen Release Agent and Checkpoint Inhibitor) pipelines that generate anti-tumor immunity when given locally (AIRISE) or systemically (ARAC) by relying on patient' s own tumor in situ as the source of antigens.

Pel-Freez Biologicals produces high quality raw materials and intermediates for biological research and diagnostic manufacturing. Our products include lyophilized tissue powders, serum products, plasma, blood complement, tissues, antibodies, and other biological raw materials. Diagnostic companies use our raw materials to develop FDA approved products, and Pel-Freez continues to manufacture products in collaboration with leading medical research universities worldwide. Please "Follow"​ our company for research and product updates as well as for staying in contact with our researchers and staff members.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PhageNova Bio is a company that has developed a targeted gene delivery vector. The company is engaged in pioneering targeted gene expression for gene therapy.

Photon Biosciences' core technology is a new ultrasensitive detection platform that combines bioengineered proteins with a uniquein vivobiomineralization process that results in a number of different genetically expressible luminescent bionanoparticles that are non-bleaching and non-blinking with luminescence intensities that rivals and surpasses many fluorescent organic molecules. The excitation and emission wavelengths of these expressible bionanoparticles can be tuned with the composition of the mineralization process and span much of the visible and near infrared regions of the electromagnetic spectrum. Because of its unique photophysical properties, PBS® has been developed into new ultrasensitive probes for biomolecular research, detection technologies, and cellular imaging.The company is developing a test to detect contamination in donated platelets.

PhotonPharma is an immuno-oncology company with a break-through technology that stimulates a patient's own immune system to seek out and destroy their cancer cells. We have a patent protected process that precisely inactivates DNA/RNA of a patient's own tumor cells while leaving the cells alive with all of unique tumor specific antigen targets (neoantigens) intact. The process is simple, fast and inexpensive. A patient's tumor cells can be extracted, inactivated and administered back on the same day. Efficacy and safety has been demonstrated in a dog trial (companion animals) and in mouse studies.

Neutralizing Antibody Discovery

Piezo Therapeutics aims to transform the delivery of nucleic acid medicines to enable improved safety, affordability, and scalability. Piezo is developing a uniquely engineered platform that uses electric pulses and microneedles to deliver a broad range of therapeutics inside the body. Its piezoelectric technology offers improved safety and efficacy, and is simple, cost-effective, and rapid to produce at scale. Founded by experts in the field of drug delivery and commercial translation, Piezo's diverse team aims to help translate the next generation of nucleic acid medicines. For more information, please visit www.piezotx.com or email partnerships@piezotx.com.

Polynoma LLC is a biotechnology company based out of 11230 Sorrento Valley Rd, San Diego, CA, United States.

Polysciences introduces Kyfora Bio, our bioprocessing brand, supporting development of cell and gene therapy (CGT) breakthroughs from bench to clinic. Backed by 60+ years of specialty chemical development, manufacturing, and application expertise, Kyfora provides research grade through cGMP transfection reagents and excipients for viral vectors, mRNA vaccines, and other drug delivery applications. Our cost-effective and scalable cGMP processes empower advanced therapies to improve patient lives.

POP Biotechnologies, Inc is Buffalo NY biotechnology company focused on the development of innovative biomedical solutions harnessing next generation nanotechnologies.

PPD is part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and its PPD clinical research business are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We offer a comprehensive suite of world-class services across the clinical development spectrum – from scientific discovery, to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product.

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting.

Primordial Genetics is a biotechnology company focused on improving the performance of bio-production systems, and enabling the development and improvement of microbes and enzymes used in pharmaceutical & industrial manufacturing and in agriculture. We develop and use whole-genome synthetic biology genetic tools to create efficient production organisms and industrial enzymes. Function Generator, the company’s flagship technology, enables rapid and flexible development of novel biological products and traits required for microbial production of amino acids, proteins, chemicals and other useful compounds. The technology is highly effective at overcoming ‘genetic black box’-type biological productivity or enzymatic activity bottlenecks that have resisted other attempts at improvement.

ProMab Biotechnologies, Inc is a revolutionizing biotechnology company that integrates cutting edge technologies to serve the global biomedical research community. We specialize in recombinant proteins, antibodies and engineered cell lines on which we are known to have built a superior reputation for quality and reliability. Our commitment to Excellence is exemplified by our newest service where we provide mRNA-LNP product and services that allows a swift and effective response to emerging infectious diseases. Join us in shaping the future of biotechnology and scientific progress. For more inquiries, visit our webiste: https://www.promab.com/. Email: info@promab.com

Protide Pharmaceuticals, Inc. is a fully integrated organization devoted to discovery, development and the advancement of technologies and processes in clinical cell therapy, regenerative medicine, transplantation and cell engineering. With over 35 years of innovative products and services, and hundreds of clinical trials using our technology, we positively impact science through knowledge. Inspired by the scientists, patients, and physicians we support, Protide continues as an entrepreneurial, science driven organization.

Rational Vaccines is a preclinical stage herpes vaccine development company actively working to improves lives with the hope of revolutionizing the treatment, prevention and diagnosis of herpes and herpes-related diseases worldwide.

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Redux Bio is an animal health product development company that creates, cultivates, and commercializes novel solutions to manage infectious disease.

Renovaro Biosciences, Inc. is a biotechnology company committed to developing advanced allogenic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as HIV and Hepatitis B virus (HBV) infection.

Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens, and regulate immune function in autoimmune disease. The company’s proprietary DECODE™ platform provides a comprehensive understanding of the interactions between T cell receptors and their antigens in disease. DECODE uniquely elucidates the entire immune synapse, including the T-cell receptor-epitope pairs that defines it, the HLA context, and the T cell phenotype. This capability enables the creation of new and potentially transformative classes of immune-based medicines. Repertoire believes the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science. The company is utilizing the discoveries from DECODE to design and develop novel immune therapies for multiple therapeutic areas, such as autoimmune diseases, infectious diseases, and cancer. The team operates from sites in Cambridge, Massachusetts and Zurich. To learn more about Repertoire, please visit www.repertoire.com.

Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology. Replicate’s off-the-shelf srRNAs contain two components: virally derived genetic code to drive controlled and self-limiting amplification, and the RNA encoding therapeutic proteins. Our library of viral vectors, selected for driving robust and sustained protein expression and orders-of-magnitude improved performance over linear mRNA, allow for the development of treatments in applications including oncology, infectious disease, and autoimmunity. Differentiated by a team of srRNA experts, a customizable library of synthetic srRNA vectors, and end-to-end development capabilities, Replicate is uniquely positioned to finally expand the reach of RNA treatments toward widespread use in infectious disease, immuno-oncology, autoimmune disease, and more.

At RNAimmune, we use mRNA technology to help people live full and healthy lives. Our primary focus is development of vaccines against cancer and respiratory viruses. Our expertise in design and production of mRNA vaccines is supported by research and development efforts toward novel lipids, targeted delivery and antigen engineering. We collaborate with the world for the health of everyone.

Rockland Antibodies is a biotechnology company that offers a wide range of antibodies for academic, biopharma, and diagnostic professionals, catering to various research and development needs.

Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.

Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.

At Sensible Biotechnologies, we are turning living cells into cost-efficient factories for manufacturing high-quality mRNA to unlock the full potential of mRNA therapeutics and vaccines. 

Sepragen Corporation is based in Union City, California. We are passionate about making a positive difference in the lives of people by providing state of the art equipment used in the manufacture of life saving biological drugs and vaccines. Our products are used by industry leaders across four continents in the manufacturing of 24 FDA approved drugs and 100s of millions of doses of two well known Covid-19 vaccines, a capacity increase we enabled in 14 weeks! Sepragen's best in class equipment enable rapid scale up from lab to production scale often in existing small footprint facilities without impacting Capex and time to market. The growing suite of products include small footprint chromatography columns, innovative standard, single-use and continuous chromatography systems, buffer making systems, and cutting edge integrated Chromatography and buffer making systems as well as novel bioreactors. We are committed to bringing our customers products that deliver many times higher performance for the same investment in money, time and infrastructure all within the framework of quality, compliance and exceptional support. Our world class products are backed by an exceptional team of high performance and committed individuals- all focused on one thing: Delivering on what we promise! To learn more about Sepragen Corporation, please visit our website at <​https://www.sepragen.com>

Formed in 2012 Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of a novel vaccine to prevent bacterial infections, including recurrent urinary tract infections (UTIs) and the treatment of certain cancers and lung infections associated with cystic fibrosis with small molecules.

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Serina Therapeutics is a privately held biotechnology company located in Huntsville, Alabama. We have developed a proprietary, clinically-validated polymer technology based on the water-soluble polymer poly(oxazoline). We call it POZ for short. Please visit our website at www.serinatherapeutics.com and review the exciting work we are doing in vaccines, Parkinson's disease, pain, oncology and cannabinoid science.

SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly. We are developing best-in-class products to treat these infections in patients worldwide.

As a premier, independently owned CDMO with over 65 years of sterile injectable manufacturing experience, Simtra BioPharma Solutions offers world-class cGMP sterile fill/finish, technical expertise, quality service, and a uniquely collaborative approach. Pharmaceutical and biotech companies partner with us when they face formulation challenges, clinical supply hurdles, surges in demand due to market fluctuations, or risk mitigation concerns. Our teams are driven to offer our clients tailored and versatile solutions to help them bring their products to market so they can get to the patients who need them. (Simtra is a tradename of Baxter Oncology GmbH and Baxter Pharmaceutical LLC)

The SingleTimeMicroneedle Patch allows vaccines to be delivered via transdermal patch that painlessly embeds bodily degradable microneedles in the skin. The microneedles can be programmed for delivery over time and at specific times, requires no refrigeration, and can be self-administered by patients. The core technology of STM is a vaccine patch which can be painlessly applied at a single time on the skin to embed arrays of microneedles (MNs) inside the superficial skin layer (like an invisible tattoo). The MNs are made of a safe biodegradable polymer (used for surgical suture) and pre-programmed to release vaccines repeatedly over a long period, mimicking the effect of multiple prime/booster doses in the traditional vaccination process. The vaccines (including subunit protein-based antigen, vector-based vaccine or mRNAs) are stabilized against high temperatures, thus avoiding the need of cold-chain storage facilities and affirming the antigenicity for a long-term skin embedment. The technology will revolutionize the vaccination process by (1) enabling a high immunogenic efficacy via transdermal delivery, (2) enhancing patient compliance via the use of painless and self-administered skin patch, and (3) removing the logistic/economic burden to store vaccines at high temperatures. This skin patch could also be applied for animal vaccination, offering a high impact on both healthcare and other industry sectors.

SmartPharm Therapeutics, now a subsidiary of Sorrento Therapeutics, is a gene therapy company applying the next generation of non-viral DNA and RNA technologies to treat serious human diseases. Founded with the vision of producing “Biologics from Within,” SmartPharm is focused on bringing together unique technology and developmental capabilities for the treatment of rare diseases including lysosomal storage disorders. SmartPharm Therapeutics is a second-generation gene-encoded therapeutics company that has benefited from the first decades of learning in gene therapy development to produce an evolved therapeutic platform. We integrate these insights with key technologies and engineering capabilities to enable us to produce optimal gene-encoded therapeutics for patients.

Autogenoues livestock vaccines and bacterins

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.  Our Specialized BioTherapeutics business segment is developing and commercializing HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203). Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®.  We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Southern Research is a nonprofit, translational scientific research organization with an 80-year legacy of moving science through drug discovery, drug development and environmental health. This legacy includes helping shape modern cancer treatment practices by developing seven FDA-approved cancer drugs and co-creating a COVID-19 vaccine currently in clinical trials. These innovations are made possible because of our greatest assets, our people that move science every day at every level of Southern Research.

Cancer patients get one chance to save their tumor tissue. Don't throw it away. Unfortunately most tissue is routinely discarded, but SpeciCare aims to change that. Your tumor tissue is as unique as a fingerprint, and holds the key to more effective, precision treatments, leading to improved outcomes, and a better quality of life. We work with cancer patients, and their care team, to uncover treatment options not available without SpeciCare's innovative protocol. Call today to speak to one of our patient advocates. We care about you.

We lead the fields of transfusion and transplantation medicine by advancing science and technology. We provide hope for the future by teaching the medical leaders of tomorrow. We enhance lives by connecting donors to patients every day.

Styx, a pioneering biotech startup, is committed to transforming immunotherapy and cancer vaccine development by emphasizing enhanced immune memory for cancer treatment and prevention, particularly for challenging cancer types. The company's pipeline includes innovative CAR-T cell therapy product candidates targeting both solid and liquid tumors, as well as vaccine candidates addressing patient populations with high unmet medical need. With a mission to develop safer, more effective, and long-lasting immunotherapies and vaccines, Styx Biotechnologies is dedicated to improving global health outcomes and fostering a healthier future for all.

SutroVax is a biopharmaceutical company that focuses on delivering best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, with a lead product candidate targeting invasive pneumococcal infections.

Syntiron LLC, is dedicated to developing innovative vaccines for humans. Our patented microbial antigen discovery and purification technology targets proteins that acquire iron, a critical nutrient that is required for survival of the bacteria. These proteins are expressed on the cell surface and are similar among different strains, making them ideal vaccine antigens. Our proprietary platform enables rapid identification of these proteins, which can then be directly extracted from the host cell or produced recombinantly for preclinical vaccine development.

SYTE.bio is a Synthetic Biology Start-Up company developing precision DNA & RNA-based therapeutics and vaccines. The company has been incorporated as a Delaware C Corp in 2021 (SYTE.bio, Inc), and has labs & offices in Argentina's headquarter, that has been operating since 2017. SYTE.bio is pioneering the development of life-changing treatments for severe diseases and vaccines to treat and prevent diseases at the molecular and cellular level using engineered DNA, improving life through innovation. SYTE.bio’s powerful redosable DNA & RNA delivery platforms will unleash the potential of personalized genetic medicine in multiple potential applications, such as Gene Therapy (Oncology, Monogenic Diseases, Cardiovascular Diseases, Vaccines, Orphan Diseases), Cell Therapy (CAR-T Therapy, Induced Pluripotent Stem Cells (iPSC)) and Gene Editing (CRISPR/Cas, TALEN, ZFN).

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: - A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; - An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; - An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity's greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio's technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.

TeselaGen provides a revolutionary DNA design and assembly protocol generation service decoupling DNA design from any underlying assembly method, providing the most advanced Bio CAD/CAM system available. Taking full advantage of both in-house DNA constructs and the rapidly falling cost of de novo DNA synthesis, TeselaGen optimizes across a broad range of modern assembly techniques to produce fully scar-less DNA sequence assembly instructions ready for use at the bench or via automation. This approach releases the biologist from the major time, cost, and functionality limitations of traditional cloning to not only deliver the best overall assembly protocol, but to also create DNA constructs that may not be achievable by any other means. With TeselaGen's proprietary technology, these advances are now available for biologists at all levels of expertise who wish to assemble DNA simply, reliably, inexpensively, and with high fidelity.

Texas Biomedical Research Institute is a biomedical research institute that focuses on advancing global health through innovative research.

Animal Vaccines

The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited. The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase 1 through to and including phase 3), and global regulatory interactions. The institute focuses on programs aimed at reducing the burden of TB, malaria, diarrheal diseases, and maternal, newborn, and child illnesses worldwide. As an affiliate of the Bill & Melinda Gates Foundation, the institute's programs are focused on disease and health areas of primary focus at the foundation. The interventions under study and development are derived from sources both within and external to the foundation.

TherapyX Inc. is changing the future of pharmaceuticals using revolutionary technology. They encapsulate large biological molecules in an orally ingestible form, allowing these molecules to remain fully intact.

The Wistar Institute is a biomedical research institution that focuses on advancing knowledge in life sciences and medical research.

Thomas Jefferson University is a private university in Philadelphia, Pennsylvania. Established in its earliest form in 1824, the university officially combined with Philadelphia University in 2017.

About Tiba Biotech Tiba Biotech is a pre-clinical stage biotechnology company revolutionizing the design and delivery of a safer, more effective and affordable generation of nucleic acid products for human and animal health. Tiba’s innovative RNA vaccine platform disrupts existing design, delivery and bio-manufacturing processes while enabling the rapid development of highly effective vaccines against multiple diseases. Privately held, Tiba is headquartered in Cambridge, Massachusetts, emanated from the Massachusetts Institute of Technology’s Koch Institute, and has strategic partnerships with the U.S. Army Medical Research Institute of Infectious Diseases and a growing list of leading research institutions. To learn more about Tiba, visit www.tiba.bio.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company’s lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company’s lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer’s disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.

TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Our other preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L1, and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. Until now, targeting biomarkers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets. TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

TregTherapeutics Inc. is a preclinical stage company focused on the treatment and cure of multiple sclerosis. The objective of the TregTherapeutics tolerogenic vaccine is to reverse the inflammatory T cell immune attack in demyelinating lesions of an MS patient, and subsequently, to create an anti-inflammatory tolerogenic response within that patient.

TRIA’s core competencies encompass the discovery and research of immune-based therapeutics. Developing vaccines for influenza, nicotine, and more.

Tulane University is a higher education institution that offers a wide range of academic programs and conducts research in various fields.

Tunnell Consulting is a consulting firm that specializes in providing operational and strategic services to the life sciences, healthcare, pharmaceutical, and biotechnology industries with a focus on regulatory compliance.

Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Our innovative TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types. Our most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer. We are also actively advancing a pipeline of preclinical programs, including TIDAL-02, our next Selected TIL program, and our TIDAL-01 and viral immunotherapy combination program.

TVAX Biomedical is a biotechnology company currently performing phase 2b/3 clinical trials to test a unique cancer immunotherapy as a treatment for pediatric brain cancer.

UbiVac is a clinical stage biotech engaged in research and development, and manufacture, of therapeutic immune activators, vaccines and cellular immunotherapies to combat cancer. Used in combination with other immunotherapies, UbiVac’s patented technologies have proven highly effective at improving survival and apparent cure in difficult to treat animal cancers (PMID: 27874054; PMID: 31747946; PMID: 22068657). UbiVac believes that the explanation for this effectiveness lies in several high impact publications from 2021 identifying a previously unknown class of shared non-mutated cancer neoantigens that make up as much as 25% of the antigens on cancer cells (PMID: 33740418; PMID: 33691108; PMID: 34663921). As the non-mutated shared cancer neoantigens are short-lived proteins, the majority are expected to be contained in UbiVac’s DPV-001. Importantly, these findings help explain why UbiVac’s immunotherapy provided cross-protective cancer immunity in preclinical models, something that had not been observed in 50 years of study (PMID: 21810919). These remarkable studies raised the possibility of off-the-shelf Universal Cancer Vaccines (PMID: 33852826). UbiVac has completed an NCI-funded phase I/II adjuvant trial of its lead agent, DPV-001. This trial met its endpoints, determined safety, identified drug formulation, and demonstrated proof-of-concept. Based on these data UbiVac partnered with the Providence Cancer Institute and Incyte on a first-in-human immunotherapy trial of UbiVac’s DPV-001, anti-GITR and anti-PD-1 for advanced HNSCC. The first patients were treated in Q4 2021, and preliminary immunological monitoring data will be presented at AACR in April 2022. UbiVac also has a pipeline of cellular therapies under development. Given that UbiVac’s CEO and CSO, together, have 55+ years of experience with preclinical and clinical studies of adoptive immunotherapy, UbiVac is well positioned to bring their innovative cellular therapy platforms to the clinic.

United Biomedical, Inc (UBI) is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases. Our product pipeline is filled with our new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. Our platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire. UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development.

Since its inception in 1969, USAMRIID has spearheaded research to develop medical solutions, vaccines, drugs, diagnostics, and information to protect military service members from biological threats. Its specialized capabilities include Biosafety Level 3 and Level 4 laboratories, world-class expertise in the generation of biological aerosols for testing candidate vaccines and therapeutics, and fully accredited animal research facilities.

Established in 1925 during the region's famous real estate boom, UM is a major research university engaged in $324 million in research and sponsored program expenditures annually. The University comprises 11 schools and colleges serving undergraduate and graduate students in more than 180 majors and programs.

Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world. Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

Vaccinex is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Our lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.

Vault Pharma’s technology platform uses the human vault particle to deliver peptide payloads for unique immune signaling. We exploit the natural function of the human vault particle which is an immunological signal alert progenitor. Natural vault function is most notably characterized by vault particles being rapidly and robustly ingested by antigen presenting cells, APCs, specifically macrophages and dendritic cells. This favorable and natural property of vaults sets in motion an elegant and robust immune response that is non-inflammatory and results in many propitious effects including stimulation of antigen specific CD4 and CD8 T cells. Recombinant Vaults Allow for Novel Access To Immune Responses Recent data in multiple animal and cell models both published and unpublished demonstrate that vaults can and do produce an elegant, sophisticated and highly desired immune response characterized by unusually high and previous undescribed cellular immune responses (both CD4 and CD8) without inflammation, or cytokine storm. Evidence demonstrates that VPI-101 elicits an enhanced TIL response which recognize and kill cancer. Furthermore, animal studies demonstrate that VPI-101 vaults down regulate the tumor immune suppressive environment; reduced immune suppressive cells (reduce effective response) like T-regulatory cells (Tregs), myeloid derived suppressor cells (MDSC), IL-10 T cells, and induce systemic antitumor responses (stimulating splenic T-cell lytic activity against parental tumor cells). Recombinant vault particles are safe and non-immunogenic. Human vaults are identical in every person; therefore, they can be delivered as an off-the-shelf therapeutic. Vaults are highly stable, scalable, and homogenous in production

For two hundred years vaccines have been administered by intramuscular injection. Vaxart’s oral vaccine pills may change everything. Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including the mouth, the nose and the gut. They are designed to trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders. Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease and VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Vaxess Technologies is a venture capital and Gates Foundation-backed life science company developing novel vaccine formulations and delivery technologies based on its proprietary silk platform. We are committed to improving access to vaccines by enabling better, more stable vaccine products that can be easily delivered all over the world. Find more information at www.vaxess.com.

Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Vernagen aims to discover and develop mRNA based therapeutics using highly advanced mRNA technologies. Our current pipeline includes vaccine platforms targeting various emerging pathogens and biologics platforms aiming to replace current protein based therapeutics. Our mRNA platforms employ multiple innovative chemical and biological components to enhance their therapeutic efficacy and safety.

Verndari was founded to advance global health by reinventing the vaccination process.Verndari, Inc. developed its patented VaxiPatch™, a complete vaccination kit that can be applied to the back of the wrist or arm. The kit contains a wipe to clean the vaccination site, the VaxiPatch™ device, and a spot bandage to cover the site post-vaccination. After vaccine administration, the VaxiPatch™ is simply peeled off the skin.The company is currently working to develop a vaccine candidate for COVID-19/

Versatope Therapeutics is an infectious disease company with two lead development programs and others at the preclinical stage. Versatope delivers immunity by customizing nano-size vesicles by using synthetic biology for biopharmaceutical applications.

At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach​ Driven by science, our mission is to revolutionize the immunotherapy treatment landscape, focusing on the development of novel, adaptable, and accessible CD8+ T cell-based technologies.​ Our transformative platform is first in its class, offering a unique methodology that combines innovative and established approaches to elicit a superior CD8+ T cell response. Novel genetically encoded checkpoint modifiers are delivered alongside optimized target-specific antigens via an immunogenic and adaptable viral vector platform that promotes potent, prolonged, and broad CD8+ T cell responses. With potential applications across a range of cancers and chronic infectious diseases, our proprietary technology provides us with a robust pipeline. Our lead product, VRON-0200, is under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV) – a first-in-human clinical study is planned to initiate in late 2022. Founded in 2018 to advance technology licensed from The Wistar Institute, we have assembled a world-class management team and an industry-leading global Board of Directors, with proven experience in the biotechnology sector, as well as extensive preclinical and clinical expertise in antiviral, vaccine, oncology, and immuno-oncology.​

Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T and bispecific antibodies. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.

VITRUVIAN BioMedical, Inc is a biotechnology company focused on a unique Business Strategy based on Early, Medium and Late Stage product development. We are committed to providing "Advance Personalized Medicine" to medical professionals and patients globally". Our strategy increases the goal of success and is implemented with key partners in the biotech and pharmaceutical industries. Our current focuse is on Alzheimer's Disease (AD) utilizing a breakthrough Therapeutic Vaccine which targets ABeta and TAU and an AD Biomarker for early stage detection.

Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldi’s DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.

VLP Therapeutics, Inc. (VLPT) was established in 2013 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland.

Washington State University is an academic institution that offers higher education and research services.

Welgen Inc is a Biotechnology company located in 25 Winthrop St, Worcester, Massachusetts, United States.

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 12,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $4.5 billion.

Wyatt Technology is a California-based developer and manufacturer of commercial light scattering instruments for sectors including medical and food and beverage.

XEME Biopharma Inc. is clinical-stage company focused on developing therapeutic products in the area of active cancer immunotherapy (vaccines). This area of therapeutic cancer vaccines is expected by many oncology specialists to provide the next breakthrough in the treatment of cancer beyond the current approaches of surgery, radiation, chemotherapy and passive immunotherapy (monoclonal antibodies). XEME Biopharma is focused on two integrated technology platforms: Aggregon® and Oncolipin. The Aggregon® technology is used in the manufacture of Oncoquest™-CLL and Oncoquest™-L, two innovative lead products of personalized (autologous) cancer vaccines for the treatment of leukemia and lymphoma, respectively. XEME's unique, disruptive, and patented technology platform has the following competitive advantages: - Indicated efficacy in previous clinical studies - Very low cost of production / high margins - Broad spectrum of potential clinical applications - personalized and off-the-shelf products - Rapid manufacturing process, less than 24 hours - Relatively low cost per dose, per patient

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Located in Frederick, MD, XpressBio is a small biotechnology company that manufactures and markets molecular and immunological products and services to the bioscience research community worldwide. Because XpressBio scientific officers are comprised of an elite group of pioneers in immunology and molecular biology, our customers are some of the world's leading pharmaceutical, biotechnology, government, and academic organizations. We are committed to satisfying our customers' expectations by providing high-quality products and services matched by superb customer service. Our research capabilities and extensive experience allow XpressBio to continuously expand its product portfolio by responding to the needs of clients for a personalized solution. Partnering with clients in this manner allows us to customize products for client needs while simultaneously expanding our product offering. Together, we can conquer manufacturing and product development challenges in a rapidly evolving environment.